← Eichor
Study identifier: NCT06514898 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

Condition: Recurrent Group 3 Medulloblastoma · Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma  ·  Sponsor: University of Florida

PhasePhase 1
Planned participants12
Who can joinAll sexes, 4 Years to 30 Years
Healthy volunteersNo

About this study

This is a pilot study in a small number of children and young adults with suspected recurrent/progressive medulloblastoma (MB) looking at the feasibility and safety of adoptive cell therapy plus PD-1 blockade.

This description comes directly from the study's public registry record.

Talk to the study team

Marcia Hodik, RN  ·  352-273-6971  ·  marcia.hodik@neurosurgery.ufl.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Florida HealthGainesville, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06514898